A Study to Evaluate Unintended Prolonged Opioid Use


About this study

The primary purpose of this study is to identify patient characteristics that are associated with unintended prolonged opioid use (UPUO).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years old.
  • No use of opioids for 6 months prior to the issuance of the initial opioid prescription.
  • Agree to use Hugo Platform on their personal smartphone or an iPad.

Exclusion Criteria:

  • Cancer-associated pain.
  • Concurrent treatment for cancer (e.g., chemotherapy, radiation therapy).
  • Residence in an extended care facility.
  • Mental health disorders that could impede functioning in an ambulatory care setting (e.g., schizophrenia, dementia).
  • Non-English speaking individuals.
  • Use of mail-order pharmacies.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

William Hooten, M.D.

Open for enrollment

Contact information:

Brenda Anderson R.N.



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available